Rathoon Ajay I, Gurusamy Venu, Ganesan Vasanth, Arivazhagan S, Yaswanth Chelikani
Department of Nephrology, SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India.
Department of Nephrology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
Indian J Nephrol. 2022 Nov-Dec;32(6):595-599. doi: 10.4103/ijn.ijn_501_21. Epub 2022 Jul 16.
Lupus nephritis (LN) is an immune complex glomerulonephritis, which is a very serious complication of systemic lupus erythematosus (SLE) as it can progress to end-stage kidney disease (ESKD).
In this study of 92 renal biopsy-proven LN, the patients were followed up for a minimum period of 2 years with a mean follow-up period of 5.4 ± 3.4 years.
The mean serum creatinine of our study population was 1.4 ± 1.53. Our study population included 2 patients with class I lesions, 5 with class II, 22 with Class III, 53 with Class IV, and 10 with Class V lesions. Our therapeutic approach included only oral steroids for class I and class II lesions; for class III, IV, and V lesions, our approach included pulse steroids followed by oral steroids with either intravenous (IV) monthly cyclophosphamide (CYC) or mycophenolate mofetil (MMF). For maintenance, azathioprine or MMF were used along with low-dose oral steroids after 6 months of CYC or MMF. In CYC induction group containing 78 patients (84.7%), 66 patients (84.6%) attained remission (CR + PR), relapse in five patients (6.4%), ESRD on HD in five patients (6.4%), and death in two patients (2.6%).
At the end of the study, in all groups, 79 patients (85.86%) were in remission (CR + PR), six patients (6.5%) were in relapse, five patients (5.4%) had reached the ESKD stage on HD, and two patients (2.2%) died.
狼疮性肾炎(LN)是一种免疫复合物性肾小球肾炎,是系统性红斑狼疮(SLE)非常严重的并发症,因为它可进展为终末期肾病(ESKD)。
在这项对92例经肾活检证实为LN的研究中,对患者进行了至少2年的随访,平均随访期为5.4±3.4年。
我们研究人群的平均血清肌酐为1.4±1.53。我们的研究人群包括2例I级病变患者、5例II级患者、22例III级患者、53例IV级患者和10例V级病变患者。我们的治疗方法包括:对于I级和II级病变仅使用口服类固醇;对于III级、IV级和V级病变,我们的方法包括脉冲类固醇治疗,随后口服类固醇,并联合静脉注射(IV)每月环磷酰胺(CYC)或霉酚酸酯(MMF)。维持治疗时,在CYC或MMF治疗6个月后,使用硫唑嘌呤或MMF并联合低剂量口服类固醇。在包含78例患者(84.7%)的CYC诱导组中,66例患者(84.6%)达到缓解(完全缓解+部分缓解),5例患者复发(6.4%),5例患者因ESRD接受血液透析(6.4%),2例患者死亡(2.6%)。
在研究结束时,所有组中,79例患者(85.86%)处于缓解状态(完全缓解+部分缓解),6例患者(6.5%)复发,5例患者因ESKD接受血液透析(5.4%),2例患者死亡(2.2%)。